Ultragenyx Pharmaceu (RARE)

$36.54 +0.09 (0.25%)
Market Cap 3.23B
Revenue (ttm) 560.23M
Net Income (ttm) -569.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -101.60%
Debt to Equity Ratio 0.00
Volume 1,242,900
Avg Vol 1,414,490
Day's Range N/A - N/A
Shares Out 96.48M
Stochastic %K 88%
Beta 0.16
Analysts Strong Sell
Price Target $81.85

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
Quantumup
Quantumup Dec. 5 at 11:05 AM
Baird reiterated $MREO Outperform-$8 and said 'Naming Mereo a Fresh Pick Ahead of Clinical Data.' $RARE Baird added, with pivotal data from the ORBIT/COSMIC studies of setrusumab in Ol weeks away (expected in December/January), we're naming Mereo a Fresh Pick, as we continue to believe the increased latitude ORBIT's final analysis provides (p-value threshold of 0.039 vs IA2 of 0.01) should result in a positive readout. Additionally, we are encouraged by Ultragenyx's recent posture surrounding the program (building inventory at risk), and note Mereo's relatively conservative valuation (which has not run up, in contrast to XBI) provides an attractive entry point.
1 · Reply
AtomicAIerts
AtomicAIerts Dec. 5 at 8:30 AM
$RARE AtomicAlerts Scalp Alert Direction: LONG Entry: $36.54 TP1: $37.24 | TP2: $37.94 | TP3: $38.64 Stop Loss: $35.94 👉 https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 5 at 3:24 AM
1ightning® Premium Options Alert (Actionable) Ticker: $RARE Contract: Dec 19 $37.5C Entry: 1.55 Exit: 2.13 Return: +37.26% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 9:59 PM
1ightning® Premium Options Alert (Actionable) Ticker: $RARE Contract: Dec 19 $37.5C Entry: 1.55 Exit: 2.13 Return: +37.26% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
WarrenPsnik
WarrenPsnik Dec. 4 at 10:00 AM
$RARE $SRPT Did well on both … sold covered calls on both to beef up the profits along the way …
0 · Reply
Iightning
Iightning Dec. 4 at 5:39 AM
1ightning® Premium Options Alert (Actionable) Ticker: $RARE Contract: Dec 19 $37.5C Entry: 2.78 Exit: 3.64 Return: +31.17% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 3 at 9:40 AM
1ightning® Premium Options Alert (Actionable) Ticker: $RARE Contract: Dec 19 $20C Entry: 37.75 Exit: 51.35 Return: +36.03% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 1 at 11:53 PM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $RARE **Contract:** Dec 19 $35C **Entry:** 1.67 **Exit:** 3.09 **Return:** **+85.31% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
RunnerSignals
RunnerSignals Nov. 28 at 9:35 PM
$CTVA $O $RARE all crossing key 200-day levels! are u ready to ride these market waves? https://stocksrunner.com/news/2025-11-28-daily-market-pulse-advanced-technical-analysis
0 · Reply
Teamtalk2014
Teamtalk2014 Nov. 26 at 2:52 PM
$MREO $RARE Stepping up sales recruitment for OI. A lot of new job postings. Sign of confidence?
2 · Reply
Latest News on RARE
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 3:23 PM EST - 1 day ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 3:13 AM EST - 2 days ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 12:26 AM EST - 4 weeks ago

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Nov 4, 2025, 4:01 PM EST - 4 weeks ago

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 4:30 PM EDT - 5 weeks ago

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 24, 2025, 4:30 PM EDT - 5 weeks ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Sep 30, 2025, 4:05 PM EDT - 2 months ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 10:13 AM EDT - 2 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 12:17 PM EDT - 3 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Sep 8, 2025, 4:05 PM EDT - 3 months ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 2:27 PM EDT - 3 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript

Ultragenyx to Participate at Investor Conferences in September

Aug 29, 2025, 4:30 PM EDT - 3 months ago

Ultragenyx to Participate at Investor Conferences in September

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Aug 18, 2025, 8:00 AM EDT - 3 months ago

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx (RARE) Q2 Revenue Up 13%

Aug 6, 2025, 10:59 AM EDT - 4 months ago

Ultragenyx (RARE) Q2 Revenue Up 13%

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 12:42 AM EDT - 4 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 5, 2025, 4:01 PM EDT - 4 months ago

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Jul 30, 2025, 8:30 AM EDT - 4 months ago

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst

Jul 29, 2025, 9:10 AM EDT - 4 months ago

Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

Jul 28, 2025, 1:16 PM EDT - 4 months ago

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

Jul 18, 2025, 3:07 PM EDT - 4 months ago

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 14, 2025, 8:14 AM EDT - 5 months ago

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

AAPL

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder

Jul 11, 2025, 4:45 PM EDT - 5 months ago

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Jul 11, 2025, 4:30 PM EDT - 5 months ago

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Jul 10, 2025, 10:06 AM EDT - 5 months ago

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Jul 10, 2025, 8:00 AM EDT - 5 months ago

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MEI

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Jul 9, 2025, 4:05 PM EDT - 5 months ago

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Jun 27, 2025, 8:00 AM EDT - 5 months ago

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 5:00 PM EDT - 6 months ago

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

May 14, 2025, 4:30 PM EDT - 7 months ago

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

May 7, 2025, 5:00 PM EDT - 7 months ago

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:31 PM EDT - 7 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

May 6, 2025, 4:01 PM EDT - 7 months ago

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Apr 30, 2025, 5:00 PM EDT - 7 months ago

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Apr 16, 2025, 9:49 AM EDT - 8 months ago

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Ultragenyx to Participate at Investor Conferences in March

Feb 24, 2025, 4:30 PM EST - 10 months ago

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 9:53 PM EST - 10 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Feb 13, 2025, 4:01 PM EST - 10 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

Feb 6, 2025, 4:30 PM EST - 10 months ago

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

Feb 5, 2025, 8:00 AM EST - 10 months ago

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

Jan 15, 2025, 2:05 PM EST - 11 months ago

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Jan 12, 2025, 11:00 AM EST - 11 months ago

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:30 PM EST - 11 months ago

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

Jan 6, 2025, 2:00 AM EST - 11 months ago

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Dec 20, 2024, 3:00 AM EST - 1 year ago

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

Dec 19, 2024, 4:05 PM EST - 1 year ago

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

Ultragenyx to Participate in Investor Conferences in December

Nov 26, 2024, 4:30 PM EST - 1 year ago

Ultragenyx to Participate in Investor Conferences in December

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 12, 2024, 11:12 AM EST - 1 year ago

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit

Nov 9, 2024, 10:30 AM EST - 1 year ago

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit

Quantumup
Quantumup Dec. 5 at 11:05 AM
Baird reiterated $MREO Outperform-$8 and said 'Naming Mereo a Fresh Pick Ahead of Clinical Data.' $RARE Baird added, with pivotal data from the ORBIT/COSMIC studies of setrusumab in Ol weeks away (expected in December/January), we're naming Mereo a Fresh Pick, as we continue to believe the increased latitude ORBIT's final analysis provides (p-value threshold of 0.039 vs IA2 of 0.01) should result in a positive readout. Additionally, we are encouraged by Ultragenyx's recent posture surrounding the program (building inventory at risk), and note Mereo's relatively conservative valuation (which has not run up, in contrast to XBI) provides an attractive entry point.
1 · Reply
AtomicAIerts
AtomicAIerts Dec. 5 at 8:30 AM
$RARE AtomicAlerts Scalp Alert Direction: LONG Entry: $36.54 TP1: $37.24 | TP2: $37.94 | TP3: $38.64 Stop Loss: $35.94 👉 https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 5 at 3:24 AM
1ightning® Premium Options Alert (Actionable) Ticker: $RARE Contract: Dec 19 $37.5C Entry: 1.55 Exit: 2.13 Return: +37.26% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 9:59 PM
1ightning® Premium Options Alert (Actionable) Ticker: $RARE Contract: Dec 19 $37.5C Entry: 1.55 Exit: 2.13 Return: +37.26% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
WarrenPsnik
WarrenPsnik Dec. 4 at 10:00 AM
$RARE $SRPT Did well on both … sold covered calls on both to beef up the profits along the way …
0 · Reply
Iightning
Iightning Dec. 4 at 5:39 AM
1ightning® Premium Options Alert (Actionable) Ticker: $RARE Contract: Dec 19 $37.5C Entry: 2.78 Exit: 3.64 Return: +31.17% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 3 at 9:40 AM
1ightning® Premium Options Alert (Actionable) Ticker: $RARE Contract: Dec 19 $20C Entry: 37.75 Exit: 51.35 Return: +36.03% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 1 at 11:53 PM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $RARE **Contract:** Dec 19 $35C **Entry:** 1.67 **Exit:** 3.09 **Return:** **+85.31% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
RunnerSignals
RunnerSignals Nov. 28 at 9:35 PM
$CTVA $O $RARE all crossing key 200-day levels! are u ready to ride these market waves? https://stocksrunner.com/news/2025-11-28-daily-market-pulse-advanced-technical-analysis
0 · Reply
Teamtalk2014
Teamtalk2014 Nov. 26 at 2:52 PM
$MREO $RARE Stepping up sales recruitment for OI. A lot of new job postings. Sign of confidence?
2 · Reply
Iightning
Iightning Nov. 26 at 2:44 AM
1ightning® Options Trade Alert (Actionable) | Buy $RARE Dec 19 $35 Call | Enter: $1.77 Exit: $2.15 | Profit: 21.00% ROI | https://1ightning.com
0 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Nov. 25 at 9:03 PM
$RARE $SRPT $QURE Highest conviction biopharm stocks heading into 2026 (and $REGN )
1 · Reply
Iightning
Iightning Nov. 25 at 12:49 PM
1ightning® Options Trade Alert (Actionable) | Buy $RARE Dec 19 $35 Call | Enter: $1.77 Exit: $2.15 | Profit: 21.00% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 1:44 AM
1ightning® Options Trade Alert (Actionable) | Buy $RARE Dec 19 $35 Call | Enter: $1.77 Exit: $2.15 | Profit: 21.00% ROI | https://1ightning.com
0 · Reply
anachartanalyst
anachartanalyst Nov. 24 at 3:02 PM
$RARE https://anachart.com/wp-content/uploads/ana_temp/1763996500_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Nov. 24 at 2:57 PM
Barclays has updated their rating for Ultragenyx Pharmaceutical ( $RARE ) to Overweight with a price target of 50.
0 · Reply
Iightning
Iightning Nov. 21 at 11:00 PM
1ightning® Options Trade Alert (Actionable) | Buy $RARE Dec 19 $35 Call | Enter: $2.25 Exit: $4.41 | Profit: 95.98% ROI | https://1ightning.com
0 · Reply
garbageshort
garbageshort Nov. 21 at 3:59 PM
$RARE $MREO copy his article and ask for logical fallacies with copilot or Gemini. The article is laughable at best...
3 · Reply
Iightning
Iightning Nov. 21 at 2:17 AM
1ightning® Options Trade Alert (Actionable) | Buy $RARE Dec 19 $35 Call | Enter: $2.25 Exit: $4.41 | Profit: 95.98% ROI | https://1ightning.com
0 · Reply
CC_Abbott
CC_Abbott Nov. 20 at 10:41 PM
$RARE $MREO If interested, my SA article https://seekingalpha.com/article/4846297?gt=a665f5615eb69ea6
5 · Reply
GunnarMeister
GunnarMeister Nov. 20 at 1:37 AM
$RARE why this drop? Algos having fun? strange...
0 · Reply
Iightning
Iightning Nov. 19 at 11:42 PM
1ightning® Options Trade Alert (Actionable) | Buy $RARE Dec 19 $35 Call | Enter: $2.25 Exit: $4.41 | Profit: 95.98% ROI | https://1ightning.com
0 · Reply